Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time

被引:77
作者
Al Dieri, R
Alban, S
Béguin, S
Hemker, HC
机构
[1] Synapse BV, Cardiovasc Res Inst, NL-6200 MD Maastricht, Netherlands
[2] Univ Kiel, Inst Pharmazeut, Abt Pharmazeut Biol, Kiel, Germany
关键词
APTT; heparin; thrombin generation;
D O I
10.1111/j.1538-7836.2004.00798.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heparin can be quantified with antifactor Xa and IIa tests (aXa, aIIa) but the anticoagulant power of heparin depends upon plasma properties as well as upon heparin concentrations and thus differs between subjects. Measuring the effect, as with the activated partial thromboplastin time (APTT) therefore is clinically more relevant. Here we investigate the use of the endogenous thrombin potential (ETP) for this purpose. In 12 volunteers 9000 IU of four heparins of different mol. wt distributions were injected. Samples were taken at 11 time points between 0 and 24 h. With the exception of the 0 and 24-h time points, heparin could be demonstrated by its aIIa and aXa activity in virtually all samples. The APTT showed the effect of this heparin in 34% of the samples; the ETP in 80%. This is partly due to the wide margins of the normal values, caused by large interindividual variation [coefficient of variation (CV) approximately 12% for the APTT, approximately 17% for the ETP]. The intraindividual variation is much smaller (CV approximately 4% for the APTT, approximately 5% for the ETP). Relative to the baseline value of the individual, the heparin effect was recognized by the APTT in 55% of the cases and by the ETP in 98%. There were no large differences between the different types of heparin.
引用
收藏
页码:1395 / 1401
页数:7
相关论文
共 38 条
[1]  
ABILDGAARD U, 1976, SCAND J CLIN LAB INV, V36, P109, DOI 10.3109/00365517609068026
[2]   The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif -: the C-domain [J].
Al Dieri, R ;
Wagenvoord, R ;
Van Dedem, GWK ;
Béguin, S ;
Hemker, HC .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (05) :907-914
[3]   Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH [J].
Alban, S ;
Welzel, D ;
Hemker, HC .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (04) :369-377
[4]  
ALHENCGELAS M, 1994, THROMB HAEMOSTASIS, V71, P698
[5]   Inability of the activated partial thromboplastin time to predict heparin levels - Time to reassess guidelines for heparin assays [J].
Baker, BA ;
Adelman, MD ;
Smith, PA ;
Osborn, JC .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (21) :2475-2479
[6]  
BEGUIN S, 1988, THROMB HAEMOSTASIS, V60, P457
[7]   HEPARIN HALF-LIFE AND SENSITIVITY IN NORMAL SUBJECTS AND IN PATIENTS AFFECTED BY DEEP-VEIN THROMBOSIS [J].
BENCHEKROUN, S ;
EYCHENNE, B ;
MERICQ, O ;
COLOMBANI, A ;
DOUSTEBLAZY, P ;
BARRET, A ;
SIE, P ;
BONEU, B .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1986, 16 (06) :536-539
[8]   VARIABILITY IN HEPARIN SENSITIVITY OF APTT REAGENTS [J].
BJORNSSON, TD ;
NASH, PV .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1986, 86 (02) :199-204
[9]   STRUCTURE-ACTIVITY RELATIONSHIP IN HEPARIN - A SYNTHETIC PENTASACCHARIDE WITH HIGH-AFFINITY FOR ANTI-THROMBIN-III AND ELICITING HIGH ANTI-FACTOR-XA ACTIVITY [J].
CHOAY, J ;
PETITOU, M ;
LORMEAU, JC ;
SINAY, P ;
CASU, B ;
GATTI, G .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1983, 116 (02) :492-499
[10]   Age-related differences in heparin sensitivity and heparin-protamine interactions in cardiac surgery patients [J].
DErrico, C ;
Shayevitz, JR ;
Martindale, SJ .
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 1996, 10 (04) :451-457